Weekly Analysts’ Ratings Changes for Danaher (DHR)

Several analysts have recently updated their ratings and price targets for Danaher (NYSE: DHR):

• 10/18/2026 – Danaher was downgraded by Wall Street Zen from “buy” to “hold”.
• 10/13/2026 – Danaher had its price target raised by TD Cowen from $236.00 to $255.00. They now have a “buy” rating on the stock.
• 10/12/2026 – Danaher had its price target raised by Morgan Stanley from $220.00 to $240.00. They now have an “overweight” rating on the stock.
• 10/10/2026 – Danaher was upgraded by Wall Street Zen from “hold” to “buy”.
• 10/7/2026 – Danaher had its price target raised by Barclays PLC from $230.00 to $255.00. They now have an “overweight” rating on the stock.
• 10/5/2026 – Danaher had its price target raised by Royal Bank Of Canada from $215.00 to $250.00. They now have an “outperform” rating on the stock.
• 10/1/2026 – Danaher had its price target raised by Guggenheim from $200.00 to $250.00. They now have a “buy” rating on the stock.
• 9/21/2026 – Danaher had its price target raised by The Goldman Sachs Group, Inc. from $210.00 to $250.00. They now have a “buy” rating on the stock.
• 9/16/2026 – Danaher was upgraded by Weiss Ratings from “hold (c-)” to “hold (c)”.
• 9/9/2026 – Danaher is now covered by UBS Group AG. They set a “buy” rating and a $250.00 price target on the stock.
• 9/9/2026 – Danaher was upgraded by UBS Group AG to “strong-buy”.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a dividend of $0.40 per share. The ex-dividend date is Wednesday, September 30th. This represents a $1.60 annualized dividend and a yield of 0.7%. Danaher’s payout ratio is presently 28.42%.

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its offerings help researchers, pharmaceutical and biotechnology companies, healthcare providers and other organizations conduct scientific research, develop and manufacture medicines, and diagnose disease.

The company operates through businesses that provide bioprocessing equipment and technologies, laboratory instruments, consumables, analytical tools and clinical diagnostic systems.